<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase II:   Nanoshell-Based Cancer Therapy</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>03/01/2005</AwardEffectiveDate>
<AwardExpirationDate>05/31/2007</AwardExpirationDate>
<AwardTotalIntnAmount>0.00</AwardTotalIntnAmount>
<AwardAmount>404156</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>F.C. Thomas Allnutt</SignBlockName>
<PO_EMAI/>
<PO_PHON/>
</ProgramOfficer>
<AbstractNarration>This Small Business Technology Transfer Research (STTR) Phase II project proposes to develop a new treatment for cancer based upon the thermal activation of gold-coated nanoparticles. This therapeutic technique involves (a) the manufacture of  new class of bio-compatible nanoparticles, optically-tunable nanoshells, designed to absorb in near-infrared wavelengths ; (b) the intravenous administration of nanoshells, which accumulate in the tumor as a result of the leaky vasculature associated with tumors ;  (c) exposure of the tumor and potential routes of metastatic spread to an external laser source at near-infrared wavelengths, which are minimally absorbed by human tissue but preferentially absorbed by nanoshells,  resulting in the generation of localized areas of heat by the nanoshells sufficient to result in  tumor regression.&lt;br/&gt; &lt;br/&gt; The commercial application of this project will be in the area of cancer therapy. There are approximately 216,000 diagnosed cases of breast cancer in the U.S. each year.  Treatment for breast cancer generally involves surgical excision, radiation, hormonal therapy and chemotherapy. The proposed treatment, offering a safer, minimally invasive  and  cheaper alternative, is expected to achieve a complete response in identified solid tumors, to treat otherwise inoperable tumors and to eliminate regional metastatic  disease before it is clinically diagnosed.  &lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>01/28/2005</MinAmdLetterDate>
<MaxAmdLetterDate>02/07/2007</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>0450484</AwardID>
<Investigator>
<FirstName>Jennifer</FirstName>
<LastName>West</LastName>
<PI_MID_INIT>L</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Jennifer L West</PI_FULL_NAME>
<EmailAddress>jennifer.l.west@duke.edu</EmailAddress>
<PI_PHON>9196605458</PI_PHON>
<NSF_ID>000490426</NSF_ID>
<StartDate>01/28/2005</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Dennis</FirstName>
<LastName>O'Neal</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Dennis O'Neal</PI_FULL_NAME>
<EmailAddress>patrick@wavegate.us</EmailAddress>
<PI_PHON>7138766652</PI_PHON>
<NSF_ID>000368760</NSF_ID>
<StartDate>01/28/2005</StartDate>
<EndDate>04/20/2005</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Jianxia</FirstName>
<LastName>Qiu</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Jianxia Qiu</PI_FULL_NAME>
<EmailAddress>JQiu@Nanospectra.com</EmailAddress>
<PI_PHON>7138422720</PI_PHON>
<NSF_ID>000365285</NSF_ID>
<StartDate>04/20/2005</StartDate>
<EndDate>02/07/2007</EndDate>
<RoleCode>Former Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Jon</FirstName>
<LastName>Schwartz</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Jon Schwartz</PI_FULL_NAME>
<EmailAddress>JSchwartz@Nanospectra.com</EmailAddress>
<PI_PHON>7138422720</PI_PHON>
<NSF_ID>000406716</NSF_ID>
<StartDate>02/07/2007</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>NANOSPECTRA BIOSCIENCES, INC.</Name>
<CityName>HOUSTON</CityName>
<CountyName>HARRIS</CountyName>
<ZipCode>770544654</ZipCode>
<PhoneNumber>7138422720</PhoneNumber>
<StreetAddress>8285 EL RIO ST STE 150</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<StateCode>TX</StateCode>
<CONGRESSDISTRICT>09</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>TX09</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>117248653</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>NANOSPECTRA BIOSCIENCES, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[NANOSPECTRA BIOSCIENCES, INC.]]></Name>
<CityName>HOUSTON</CityName>
<CountyName>HARRIS</CountyName>
<StateCode>TX</StateCode>
<ZipCode>770544654</ZipCode>
<StreetAddress><![CDATA[8285 EL RIO ST STE 150]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Texas</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>09</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>TX09</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<FoaInformation>
<Code>0110000</Code>
<Name>Technology Transfer</Name>
</FoaInformation>
<FoaInformation>
<Code>0203000</Code>
<Name>Health</Name>
</FoaInformation>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramElement>
<Code>1591</Code>
<Text>STTR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>9178</Code>
<Text>UNDERGRADUATE EDUCATION</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>9251</Code>
<Text>REU SUPP-Res Exp for Ugrd Supp</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
<Appropriation>
<Code>0105</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>490100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2005~404156</FUND_OBLG>
</Award>
</rootTag>
